ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

Elotuzumab, targeting signaling lymphocytic activation molecule family 7 (SLAMF7), has been approved in combination with lenalidomide and dexamethasone   (ELd)   for relapsed/refractory  multiple myeloma (MM) based on the findings of the phase III randomized trial  ELOQUENT-2 (NCT01239797). Four-yea...

Full description

Bibliographic Details
Main Authors: Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko
Format: Article
Language:English
Published: PAGEPress Publications 2018-02-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Elotuzumab
multiple myeloma
SLAMF7
SLAM-associated protein (SAP)
EAT-2
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/3270

Internet

https://www.mjhid.org/index.php/mjhid/article/view/3270

Similar Items